Seeking Alpha

Shares of Halozyme (HALO) shoot up 29% premarket after the firm announces positive results from...

Shares of Halozyme (HALO) shoot up 29% premarket after the firm announces positive results from a Phase 3 HannaH trial of its breast cancer treatment, Herceptin, given by subcutaneous injection.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|